介绍
本页面提供了有关 Mark N Lampert 已知的内部交易历史的全面分析。内部人士包括公司的高管、董事或重要投资者。一般而言,基于内幕、非公开信息进行交易是非法的。这并不意味着他们在自己的公司进行任何交易都是非法的。但是,他们必须通过Form 4向美国证券交易委员会(SEC)报告所有交易。尽管存在这些限制,学术研究表明,整体而言,内部人士在自己公司中的投资表现往往优于市场。
平均交易盈利能力
“平均交易盈利能力”衡量了内部人士在过去三年中所有非计划性的公开市场买入交易的平均回报率。计算过程包括检查每笔交易,排除了作为10b5-1交易计划的一部分的交易。然后,对每笔交易在3、6和12个月的表现进行平均,以生成该笔交易最终的表现指标。然后,将所有交易的表现指标进行平均,计算出内部人士的总体平均表现指标。列表仅包含在过去两年中进行过至少三笔交易的内部人士。
如果内部人士的交易盈利能力显示为"N/A",则可能是因为该内部人士在过去三年内没有进行任何公开市场买入交易,或者他们进行的交易距离现在时间太近,无法计算出可靠的表现指标。
更新频率:每日
报告内部持仓的公司
美国证券交易委员会(SEC)文件显示Mark N Lampert已报告在以下公司拥有持仓或进行了交易:
如何解读这些图表
以下图表显示了在Mark N Lampert进行的每笔公开市场非计划交易后证券的股价表现。非计划交易是指没有作为10b5-1交易计划的一部分而进行的交易。股价表现以累积百分比变化的方式绘制。例如,如果一笔内部人士交易是在2019年1月1日进行的,该图表将显示该证券的每日百分比变化直至当前日期。如果在此期间股价从10美元涨至15美元,则股价的累积百分比变化将为50%。从10美元涨至20美元的价格变化将为100%,而从10美元跌至5美元的价格变化将为-50%。
最终,我们将评估内部人士的交易与股价的超额回报(正向或负向)之间的相关性,以判断内部人士是否在交易中利用内部信息获利。如果内部人士有这样的行为,我们预期看到(a)买入后的正回报,或者(b)卖出后的负回报。对于情况(a),买入图表将显示一系列向上倾斜的曲线,表示每次买入后都有正回报。对于情况(b),卖出图表将显示一系列向下倾斜的曲线,表示每次卖出后都有负回报。
然而,仅凭这一点还不足以得出结论。例如,如果公司的股价在多年内呈现非周期性上升,我们会预期所有买入后的图表都呈现向上倾斜。同样地,多年来呈现非周期性下降的股价会导致卖出后的图表也呈现向下倾斜。这两种情况的图表都不能表示内部人士在进行内幕交易。
最有力的指标是在公司股价呈极度循环波动的情况下,“买入”图表显示正向信号,而“卖出”图表显示负向趋势。这种情况强烈暗示内部人士可能根据内幕信息精确地计时进行交易,以获得财务优势。
CALA / Calithera Biosciences, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CALA / Calithera Biosciences, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CAPS / Capstone Holding Corp.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
CAPS / Capstone Holding Corp.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CGEM / Cullinan Therapeutics, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CGEM / Cullinan Therapeutics, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
CTMX / CytomX Therapeutics, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
CTMX / CytomX Therapeutics, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
CYTK / Cytokinetics, Incorporated内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CYTK / Cytokinetics, Incorporated内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
ELDN / Eledon Pharmaceuticals, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
ELDN / Eledon Pharmaceuticals, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
EPIX / ESSA Pharma Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
EPIX / ESSA Pharma Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
FDMT / 4D Molecular Therapeutics, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
FDMT / 4D Molecular Therapeutics, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
IDYA / IDEAYA Biosciences, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
IDYA / IDEAYA Biosciences, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
INFIQ / Infinity Pharmaceuticals, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
INFIQ / Infinity Pharmaceuticals, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
KYMR / Kymera Therapeutics, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
KYMR / Kymera Therapeutics, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
MLTX / MoonLake Immunotherapeutics内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
MLTX / MoonLake Immunotherapeutics内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
MRUS / Merus N.V.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
MRUS / Merus N.V.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
OLMA / Olema Pharmaceuticals, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
OLMA / Olema Pharmaceuticals, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
RIGL / Rigel Pharmaceuticals, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
RIGL / Rigel Pharmaceuticals, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
RPTX / Repare Therapeutics Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
RPTX / Repare Therapeutics Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
SNDX / Syndax Pharmaceuticals, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
SNDX / Syndax Pharmaceuticals, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
VSTM / Verastem, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
VSTM / Verastem, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
XENE / Xenon Pharmaceuticals Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
XENE / Xenon Pharmaceuticals Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
XOMAO / XOMA Royalty Corporation - Preferred Stock内部人士买入 - 短期收益分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
XOMAO / XOMA Royalty Corporation - Preferred Stock内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 CALA / Calithera Biosciences, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
内幕交易历史
该表格显示了由 Mark N Lampert 进行的所有内幕交易的完整列表,这些交易已向美国证券交易委员会(SEC)披露。
备案日期 | 交易日期 | 表格 | 股票代码 | 证券 | 代码 | 股数 | 剩余股数 | % 变化 |
每股 股价 |
交易 金额 |
剩余 金额 |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -11 | 560,797 | 0.00 | 1.88 | -21 | 1,053,121 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -66 | 4,726,743 | 0.00 | 1.88 | -124 | 8,876,351 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
S - Sale | -79 | 6,194,145 | 0.00 | 1.88 | -148 | 11,631,985 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 203,336 | 560,808 | 56.88 | 0.00 | 20 | 56 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,235,030 | 4,726,809 | 35.37 | 0.00 | 124 | 473 | |
2025-08-07 |
|
4 | EPIX |
ESSA Pharma Inc.
Common Stock |
X - Other | 1,481,634 | 6,194,224 | 31.44 | 0.00 | 148 | 619 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,780 | 353,412 | 19.95 | 44.00 | 2,586,320 | 15,550,128 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 115,783 | 2,219,858 | 5.50 | 44.00 | 5,094,452 | 97,673,752 | |
2025-07-01 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142,604 | 2,798,795 | 5.37 | 44.00 | 6,274,576 | 123,146,980 | |
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 56,079 | 62,383 | 889.58 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 556,617 | 593,740 | 1,499.39 | ||||
2025-06-17 |
|
4 | CBIO |
GLYCOMIMETICS INC
Common Stock |
J - Other | 657,308 | 707,116 | 1,319.68 | ||||
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -265,316 | 1,267,545 | -17.31 | 27.10 | -7,190,064 | 34,350,470 | |
2025-05-20 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -127,407 | 1,322,758 | -8.79 | 27.10 | -3,452,730 | 35,846,742 | |
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -855,211 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -6,777,935 | 0 | -100.00 | ||||
2025-05-19 |
|
4 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
D - Sale to Issuer | -8,679,726 | 0 | -100.00 | ||||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -149,975 | 0 | -100.00 | 26.10 | -3,914,348 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -75,287 | 0 | -100.00 | 26.10 | -1,964,991 | ||
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -85,776 | 1,532,861 | -5.30 | 26.10 | -2,238,754 | 40,007,672 | |
2025-01-28 |
|
4 | XOMA |
XOMA Royalty Corp
Common Stock, $0.0075 par value per share |
S - Sale | -339,679 | 1,450,165 | -18.98 | 26.10 | -8,865,622 | 37,849,306 | |
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -22,740 | 347,970 | -6.13 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -161,810 | 2,003,966 | -7.47 | ||||
2025-01-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -235,450 | 2,655,977 | -8.14 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 29,648 | 38,961 | 318.35 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 174,958 | 282,223 | 163.11 | ||||
2024-12-17 |
|
4 | PVLA |
PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value |
J - Other | 234,323 | 371,916 | 170.30 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -153,441 | 370,710 | -29.27 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,418,736 | 2,165,776 | -39.58 | ||||
2024-12-04 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
D - Sale to Issuer | -1,797,527 | 2,891,427 | -38.34 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -240,000 | 87,911 | -73.19 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -2,378,000 | 662,970 | -78.20 | ||||
2024-11-13 |
|
4 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
J - Other | -3,062,000 | 830,237 | -78.67 | ||||
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -64,617 | 176,692 | -26.78 | 14.30 | -924,023 | 2,526,696 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -396,963 | 1,367,257 | -22.50 | 14.30 | -5,676,571 | 19,551,775 | |
2024-10-31 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
S - Sale | -538,420 | 1,794,218 | -23.08 | 14.30 | -7,699,406 | 25,657,317 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -132,549 | 1,287,768 | -9.33 | 50.00 | -6,627,662 | 64,390,460 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -836,862 | 8,168,838 | -9.29 | 50.00 | -41,844,439 | 408,454,970 | |
2024-10-08 |
|
4 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
S - Sale | -1,030,589 | 10,235,089 | -9.15 | 50.00 | -51,531,099 | 511,770,826 | |
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,892,237 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
3,040,970 | ||||||||
2024-08-01 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value |
327,911 | ||||||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,431 | 220,460 | 52.01 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 821,121 | 2,633,679 | 45.30 | ||||
2024-05-13 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,031,385 | 3,361,803 | 44.26 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -341,547 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -185,388 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,076,085 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,367,838 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value |
U - Other | -2,870,985 | 0 | -100.00 | ||||
2024-01-29 |
|
4 | RAIN |
Rain Oncology Inc.
Common Stock, $0.001 par value |
U - Other | -1,734,960 | 0 | -100.00 | ||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
8,679,726 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
6,777,935 | ||||||||
2024-01-26 | 3 | ALLK |
Allakos Inc.
Common Stock, $0.001 par value |
855,211 | ||||||||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -896,366 | 0 | -100.00 | 12.45 | -11,159,757 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -7,290,667 | 0 | -100.00 | 12.45 | -90,768,804 | ||
2023-12-20 |
|
4 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
S - Sale | -8,974,245 | 0 | -100.00 | 12.45 | -111,729,350 | ||
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 16,143 | 548,938 | 3.03 | 5.38 | 86,909 | 2,955,318 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 125,909 | 4,308,573 | 3.01 | 5.38 | 677,856 | 23,196,064 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 153,693 | 5,309,432 | 2.98 | 5.38 | 827,437 | 28,584,389 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 47,712 | 532,795 | 9.84 | 5.00 | 238,555 | 2,663,922 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 390,507 | 4,182,664 | 10.30 | 5.00 | 1,952,496 | 20,912,902 | |
2023-11-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 493,337 | 5,155,739 | 10.58 | 5.00 | 2,466,636 | 25,778,179 | |
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
1,204,412 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
912,776 | ||||||||
2023-11-13 | 3 | ENGN |
enGene Holdings Inc.
Class A Common Shares |
104,257 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
8,974,245 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
7,290,667 | ||||||||
2023-11-06 | 3 | PNT |
POINT Biopharma Global Inc.
Common Stock, $0.0001 par value |
896,366 | ||||||||
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,106 | 294,632 | 3.55 | 14.07 | 142,180 | 4,145,148 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 83,708 | 2,104,075 | 4.14 | 14.07 | 1,177,679 | 29,602,021 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 103,885 | 2,656,191 | 4.07 | 14.07 | 1,461,548 | 37,369,686 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,772 | 284,526 | 10.39 | 11.64 | 311,744 | 3,313,135 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 132,016 | 2,020,367 | 6.99 | 11.64 | 1,537,247 | 23,525,961 | |
2023-11-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,618 | 2,552,306 | 2.31 | 11.64 | 670,927 | 29,720,072 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 72,479 | 485,083 | 17.57 | 3.60 | 260,924 | 1,746,299 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 492,251 | 3,792,157 | 14.92 | 3.60 | 1,772,104 | 13,651,765 | |
2023-11-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 218,979 | 4,662,402 | 4.93 | 3.60 | 788,324 | 16,784,647 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 52,801 | 524,151 | 11.20 | 9.84 | 519,562 | 5,157,646 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 677,853 | 3,584,512 | 23.32 | 9.84 | 6,670,074 | 35,271,598 | |
2023-09-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 775,278 | 4,688,954 | 19.81 | 9.84 | 7,628,736 | 46,139,307 | |
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -43,139 | 0 | -100.00 | 9.10 | -392,565 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -1,526,147 | 0 | -100.00 | 9.10 | -13,887,938 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -702,505 | 0 | -100.00 | 9.10 | -6,392,796 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -2,595,239 | 0 | -100.00 | 9.10 | -23,616,675 | ||
2023-06-28 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
U - Other | -3,989,130 | 0 | -100.00 | 9.10 | -36,301,083 | ||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
11,007,420 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
8,581,171 | ||||||||
2023-05-22 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
744,966 | ||||||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -462,605 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -2,929,660 | 0 | -100.00 | ||||
2023-05-12 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
J - Other | -4,018,253 | 0 | -100.00 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 86,341 | 145,029 | 147.12 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 837,146 | 1,812,558 | 85.82 | ||||
2023-05-09 |
|
4 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,055,445 | 2,330,418 | 82.78 | ||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
4,018,253 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,801,529 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,929,660 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
2,130,657 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
462,605 | ||||||||
2023-02-13 | 3 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share |
241,755 | ||||||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -300,000 | 64,161 | -82.38 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -2,600,000 | 392,808 | -86.87 | ||||
2023-01-19 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
J - Other | -3,500,000 | 558,854 | -86.23 | ||||
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 15,912 | 1,888,351 | 0.85 | 31.24 | 497,132 | 58,996,995 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2,985 | 2,494,688 | 0.12 | 31.24 | 93,259 | 77,940,539 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,149 | 1,872,439 | 0.60 | 29.89 | 333,209 | 55,961,397 | |
2023-01-13 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,961 | 2,491,703 | 0.44 | 29.89 | 327,590 | 74,469,278 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,573 | 1,618,637 | 0.10 | 21.98 | 34,577 | 35,580,393 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,676 | 1,789,844 | 0.09 | 21.98 | 36,841 | 39,343,814 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 15,670 | 1,617,064 | 0.98 | 18.39 | 288,096 | 29,730,045 | |
2023-01-09 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,330 | 1,788,168 | 0.19 | 18.39 | 61,223 | 32,875,826 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 9,597 | 241,309 | 4.14 | 4.11 | 39,430 | 991,442 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 87,831 | 1,764,220 | 5.24 | 4.11 | 360,862 | 7,248,474 | |
2022-12-22 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 116,635 | 2,332,638 | 5.26 | 4.11 | 479,207 | 9,583,876 | |
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
2,216,003 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
1,676,389 | ||||||||
2022-12-22 | 3 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
231,712 | ||||||||
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 54,857 | 341,547 | 19.13 | 5.83 | 319,816 | 1,991,219 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 685,330 | 2,076,085 | 49.28 | 5.83 | 3,995,474 | 12,103,576 | |
2022-11-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
P - Purchase | 970,171 | 2,870,985 | 51.04 | 5.83 | 5,656,097 | 16,737,843 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 678 | 1,601,394 | 0.04 | 16.89 | 11,452 | 27,047,865 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,004 | 1,784,838 | 0.06 | 16.89 | 16,958 | 30,146,271 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,021 | 1,600,716 | 0.19 | 16.83 | 50,849 | 26,942,771 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,339 | 1,783,834 | 0.19 | 16.83 | 56,201 | 30,024,959 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,885 | 1,597,695 | 0.62 | 16.50 | 163,073 | 26,357,174 | |
2022-09-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,715 | 1,780,495 | 0.38 | 16.50 | 110,777 | 29,372,826 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,396 | 1,773,780 | 0.76 | 17.89 | 239,618 | 31,728,135 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,897 | 1,587,810 | 0.69 | 17.89 | 194,918 | 28,401,634 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,575 | 1,576,913 | 0.35 | 17.96 | 100,138 | 28,324,511 | |
2022-09-16 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 26,441 | 1,571,338 | 1.71 | 17.25 | 456,044 | 27,101,809 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,117 | 257,754 | 11.76 | 26.00 | 705,042 | 6,701,604 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 233,362 | 1,861,290 | 14.33 | 26.00 | 6,067,412 | 48,393,540 | |
2022-08-23 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 285,046 | 2,480,742 | 12.98 | 26.00 | 7,411,196 | 64,499,292 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 1,519,999 | 1,526,147 | 24,723.47 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -1,289,434 | 6,148 | -99.53 | 6.12 | -7,891,336 | 37,626 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 682,666 | 702,505 | 3,441.03 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -469,040 | 19,839 | -95.94 | 6.12 | -2,870,525 | 121,415 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 2,426,666 | 2,595,239 | 1,439.53 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -2,890,723 | 168,573 | -94.49 | 6.12 | -17,691,225 | 1,031,667 | |
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
C - Conversion | 3,754,000 | 3,989,130 | 1,596.56 | ||||
2022-08-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
S - Sale | -3,850,803 | 235,130 | -94.25 | 6.12 | -23,566,914 | 1,438,996 | |
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
4,712,590 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
3,491,779 | ||||||||
2022-07-21 | 3 | EPIX |
ESSA Pharma Inc.
Common Stock |
357,472 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
2,132,411 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
1,570,857 | ||||||||
2022-06-27 | 3 | FDMT |
4D Molecular Therapeutics, Inc.
Common Stock |
209,716 | ||||||||
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 6,168 | 412,604 | 1.52 | 12.73 | 78,519 | 5,252,449 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 68,327 | 3,299,906 | 2.11 | 12.73 | 869,803 | 42,007,803 | |
2022-06-15 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 74,666 | 4,443,423 | 1.71 | 12.73 | 950,498 | 56,564,775 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 41,417 | 2,906,659 | 1.45 | 4.03 | 167,097 | 11,726,916 | |
2022-06-14 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 158,583 | 3,913,676 | 4.22 | 4.03 | 639,803 | 15,789,726 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 20 | 406,436 | 0.00 | 13.21 | 264 | 5,369,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,040 | 3,231,579 | 0.09 | 13.21 | 40,164 | 42,694,975 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 3,809 | 4,368,757 | 0.09 | 13.21 | 50,324 | 57,719,144 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 31,903 | 406,416 | 8.52 | 12.29 | 391,960 | 4,993,227 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 258,797 | 3,228,539 | 8.71 | 12.29 | 3,179,580 | 39,665,830 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 353,344 | 4,364,948 | 8.81 | 12.29 | 4,341,184 | 53,627,751 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 61,156 | 374,513 | 19.52 | 11.68 | 714,449 | 4,375,211 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 464,235 | 2,969,742 | 18.53 | 11.68 | 5,423,379 | 34,693,714 | |
2022-06-06 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 660,654 | 4,011,604 | 19.72 | 11.68 | 7,718,024 | 46,865,163 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 44,746 | 364,161 | 14.01 | 11.00 | 492,179 | 4,005,553 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 301,009 | 2,992,808 | 11.18 | 11.00 | 3,310,918 | 32,919,092 | |
2022-06-03 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 405,641 | 4,058,854 | 11.10 | 11.00 | 4,461,808 | 44,644,959 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 3,223 | 230,637 | 1.42 | 14.78 | 47,645 | 3,409,461 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26,353 | 1,627,928 | 1.65 | 14.78 | 389,571 | 24,065,334 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 35,793 | 2,195,696 | 1.66 | 14.78 | 529,121 | 32,458,535 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,642 | 227,414 | 4.91 | 14.21 | 151,229 | 3,231,689 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 90,372 | 1,601,575 | 5.98 | 14.21 | 1,284,240 | 22,759,342 | |
2022-05-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 123,043 | 2,159,903 | 6.04 | 14.21 | 1,748,515 | 30,693,518 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37 | 216,772 | 0.02 | 14.00 | 518 | 3,034,678 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,180 | 1,511,203 | 0.28 | 14.00 | 58,517 | 21,155,935 | |
2022-05-24 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5,883 | 2,036,860 | 0.29 | 14.00 | 82,358 | 28,514,818 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 5,730 | 313,357 | 1.86 | 8.50 | 48,705 | 2,663,534 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 189,882 | 2,505,507 | 8.20 | 8.50 | 1,613,997 | 21,296,810 | |
2022-05-20 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 224,388 | 3,350,950 | 7.18 | 8.50 | 1,907,298 | 28,483,075 | |
2022-05-20 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 8,996 | 8,996 | |||||
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 17,744 | 319,415 | 5.88 | 9.14 | 162,091 | 2,917,856 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 38,558 | 2,691,799 | 1.45 | 9.14 | 352,227 | 24,589,584 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 53,598 | 3,653,213 | 1.49 | 9.14 | 489,618 | 33,372,101 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 457,001 | 2,653,241 | 20.81 | 9.06 | 4,140,429 | 24,038,363 | |
2022-05-16 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 542,999 | 3,599,615 | 17.76 | 9.06 | 4,919,571 | 32,612,512 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,131 | 216,735 | 1.94 | 19.26 | 79,542 | 4,173,232 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 40,659 | 1,507,023 | 2.77 | 19.26 | 782,889 | 29,017,728 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55,210 | 2,030,977 | 2.79 | 19.26 | 1,063,069 | 39,106,462 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4,066 | 212,604 | 1.95 | 19.60 | 79,690 | 4,166,847 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 70,439 | 1,466,364 | 5.05 | 19.60 | 1,380,541 | 28,739,415 | |
2022-05-09 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 75,495 | 1,975,767 | 3.97 | 19.60 | 1,479,634 | 38,723,255 | |
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
11,265,678 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
9,005,699 | ||||||||
2022-04-15 | 3 | MLTX |
MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value |
1,420,317 | ||||||||
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 9,402 | 2,196,240 | 0.43 | 10.75 | 101,071 | 23,609,360 | |
2022-04-05 |
|
4 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
P - Purchase | 266,598 | 3,056,616 | 9.56 | 10.75 | 2,865,902 | 32,858,316 | |
2022-03-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
10,753,294 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
7,883,287 | ||||||||
2022-02-07 | 3 | VSTM |
Verastem, Inc.
Common Stock |
994,353 | ||||||||
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,323 | 1,395,925 | 1.04 | 40.70 | 582,946 | 56,814,148 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20,085 | 1,900,272 | 1.07 | 40.70 | 817,460 | 77,341,070 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 37,859 | 1,381,602 | 2.82 | 38.33 | 1,451,207 | 52,959,430 | |
2022-01-31 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 58,042 | 1,880,187 | 3.19 | 38.33 | 2,224,860 | 72,071,140 | |
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
1,274,973 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
975,412 | ||||||||
2022-01-31 | 3 | ELDN |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
58,688 | ||||||||
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 114,726 | 1,343,743 | 9.33 | 37.76 | 4,332,455 | 50,744,439 | |
2022-01-26 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 158,041 | 1,822,145 | 9.50 | 37.76 | 5,968,181 | 68,810,573 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 7,899 | 307,627 | 2.64 | 14.10 | 111,376 | 4,337,541 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 412,264 | 2,315,625 | 21.66 | 14.10 | 5,812,922 | 32,650,312 | |
2022-01-21 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares, no par value |
P - Purchase | 577,798 | 3,126,562 | 22.67 | 14.10 | 8,146,952 | 44,084,524 | |
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,790,018 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
2,186,838 | ||||||||
2022-01-10 | 3 | CGEM |
Cullinan Oncology, Inc.
Common Stock |
301,671 | ||||||||
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,806 | 185,388 | 8.68 | 12.00 | 177,672 | 2,224,656 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 226,079 | 1,367,838 | 19.80 | 12.00 | 2,712,948 | 16,414,056 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 255,500 | 1,734,960 | 17.27 | 12.00 | 3,066,000 | 20,819,520 | |
2022-01-10 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 61,343 | 1,141,759 | 5.68 | 12.00 | 736,018 | 13,699,281 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 35,268 | 471,350 | 8.09 | 9.39 | 331,177 | 4,426,118 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 341,977 | 2,865,242 | 13.55 | 9.39 | 3,211,267 | 26,905,482 | |
2021-12-02 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 362,430 | 3,755,093 | 10.68 | 9.39 | 3,403,326 | 35,261,450 | |
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
2,548,764 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
1,903,361 | ||||||||
2021-11-08 | 3 | RPTX |
Repare Therapeutics Inc.
Common Stock |
299,728 | ||||||||
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -8,929 | 232,747 | -3.69 | 27.79 | -248,106 | 6,467,225 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -58,327 | 1,520,405 | -3.69 | 27.79 | -1,620,703 | 42,246,734 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -80,011 | 2,085,664 | -3.69 | 27.79 | -2,223,226 | 57,953,303 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -69,534 | 241,676 | -22.34 | 27.53 | -1,914,348 | 6,653,606 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -384,914 | 1,578,732 | -19.60 | 27.53 | -10,597,106 | 43,464,229 | |
2021-10-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -530,999 | 2,165,675 | -19.69 | 27.53 | -14,618,987 | 59,623,415 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 590 | 170,582 | 0.35 | 13.94 | 8,226 | 2,378,357 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,102 | 1,080,416 | 0.38 | 13.94 | 57,193 | 15,063,808 | |
2021-09-23 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,341 | 1,479,460 | 0.43 | 13.94 | 88,410 | 20,627,519 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,512 | 169,992 | 13.72 | 16.49 | 338,243 | 2,803,168 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 158,511 | 1,076,314 | 17.27 | 16.49 | 2,613,846 | 17,748,418 | |
2021-09-15 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 213,246 | 1,473,119 | 16.93 | 16.49 | 3,516,427 | 24,291,732 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -150,805 | 311,210 | -32.64 | 20.75 | -3,129,204 | 6,457,608 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -928,739 | 1,963,646 | -32.11 | 20.75 | -19,271,334 | 40,745,654 | |
2021-07-07 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
S - Sale | -1,106,478 | 2,696,674 | -29.09 | 20.75 | -22,959,418 | 55,955,986 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 27,458 | 208,538 | 15.16 | 47.00 | 1,290,526 | 9,801,286 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 211,711 | 1,229,017 | 20.81 | 47.00 | 9,950,417 | 57,763,799 | |
2021-07-06 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 304,997 | 1,664,104 | 22.44 | 47.00 | 14,334,859 | 78,212,888 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,980 | 149,480 | 12.82 | 15.25 | 258,945 | 2,279,570 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 106,627 | 917,803 | 13.14 | 15.25 | 1,626,062 | 13,996,496 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 146,116 | 1,259,873 | 13.12 | 15.25 | 2,228,269 | 19,213,063 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,018 | 132,500 | 17.80 | 15.65 | 313,282 | 2,073,625 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 124,804 | 811,176 | 18.18 | 15.65 | 1,953,183 | 12,694,904 | |
2021-07-06 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 172,457 | 1,113,757 | 18.32 | 15.65 | 2,698,952 | 17,430,297 | |
2021-06-21 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 20,063 | 20,063 | |||||
2021-05-26 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
J - Other | 99,556 | 99,556 | |||||
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 129 | 112,482 | 0.11 | 15.90 | 2,050 | 1,787,924 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 513 | 686,372 | 0.07 | 15.90 | 8,154 | 10,910,020 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 719 | 941,300 | 0.08 | 15.90 | 11,429 | 14,962,152 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 7,592 | 112,353 | 7.25 | 15.94 | 121,032 | 1,791,132 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 48,152 | 685,859 | 7.55 | 15.94 | 767,639 | 10,933,964 | |
2021-05-25 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 66,242 | 940,581 | 7.58 | 15.94 | 1,056,030 | 14,994,742 | |
2021-05-21 |
|
4 | XOMA |
XOMA Corp
Non-Qualified Stock Option (right to buy) |
A - Award | 5,101 | 5,101 | |||||
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,115 | 104,761 | 1.08 | 15.88 | 17,711 | 1,664,055 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,962 | 637,707 | 1.10 | 15.88 | 110,586 | 10,129,529 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,191 | 874,339 | 1.06 | 15.88 | 145,993 | 13,888,263 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 11,946 | 103,646 | 13.03 | 16.65 | 198,901 | 1,725,706 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 75,640 | 630,745 | 13.63 | 16.65 | 1,259,406 | 10,501,904 | |
2021-05-20 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 103,611 | 865,148 | 13.61 | 16.65 | 1,725,123 | 14,404,714 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-05-17 |
|
4/A | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,474 | 91,700 | 3.94 | 14.26 | 49,544 | 1,307,780 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,721 | 555,105 | 4.27 | 14.26 | 324,036 | 7,916,630 | |
2021-05-17 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
P - Purchase | 31,805 | 761,537 | 4.36 | 14.26 | 453,587 | 10,860,660 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 1,747 | 88,226 | 2.02 | 14.90 | 26,032 | 1,314,647 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 10,876 | 532,384 | 2.09 | 14.90 | 162,062 | 7,933,001 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 14,790 | 729,732 | 2.07 | 14.90 | 220,384 | 10,873,664 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -134,515 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -152,176 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -17,390 | 152,176 | -10.26 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -837,397 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -553,359 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -84,350 | 553,359 | -13.23 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,068,554 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -832,261 | 0 | -100.00 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Series A Convertible Preferred Stock |
C - Conversion | -115,293 | 832,261 | -12.17 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 134,515 | 286,691 | 88.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 152,176 | 152,176 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 6,141 | 86,479 | 7.64 | 15.93 | 97,817 | 1,377,481 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 62,948 | 80,338 | 361.98 | 17.00 | 1,070,116 | 1,365,746 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 17,390 | 17,390 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 837,397 | 1,390,756 | 151.33 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 553,359 | 553,359 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 38,858 | 521,508 | 8.05 | 15.93 | 618,950 | 8,306,840 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 398,300 | 482,650 | 472.20 | 17.00 | 6,771,100 | 8,205,050 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 84,350 | 84,350 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 1,068,554 | 1,900,815 | 128.39 | ||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value |
C - Conversion | 832,261 | 832,261 | |||||
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 53,303 | 714,942 | 8.06 | 15.93 | 849,037 | 11,387,954 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
A - Award | 546,346 | 661,639 | 473.88 | 17.00 | 9,287,882 | 11,247,863 | |
2021-04-27 |
|
4 | RAIN |
Rain Therapeutics Inc.
Common Stock, $0.001 par value |
C - Conversion | 115,293 | 115,293 | |||||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 17 | 17 | 25,000.00 | 425,000 | 425,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 239 | 239 | 25,000.00 | 5,975,000 | 5,975,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock |
P - Purchase | 344 | 344 | 25,000.00 | 8,600,000 | 8,600,000 | ||
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 5,171 | 488,879 | 1.07 | 2.50 | 12,928 | 1,222,198 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 950,016 | 3,059,296 | 45.04 | 2.50 | 2,375,040 | 7,648,240 | |
2021-04-05 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 1,044,813 | 4,085,933 | 34.36 | 2.50 | 2,612,032 | 10,214,832 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -81,903 | 149,975 | -35.32 | 38.36 | -3,141,799 | 5,753,041 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -84,250 | 75,287 | -52.81 | 38.36 | -3,231,830 | 2,888,009 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -205,807 | 1,544,897 | -11.76 | 38.36 | -7,894,757 | 59,262,249 | |
2021-04-02 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
S - Sale | -279,740 | 1,760,384 | -13.71 | 38.36 | -10,730,826 | 67,528,330 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 26,894 | 462,015 | 6.18 | 19.75 | 531,156 | 9,124,796 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 108,106 | 2,892,385 | 3.88 | 19.75 | 2,135,094 | 57,124,604 | |
2021-04-01 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 165,000 | 3,803,152 | 4.54 | 19.75 | 3,258,750 | 75,112,252 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 7,744 | 435,121 | 1.81 | 22.75 | 176,176 | 9,899,003 | |
2021-03-24 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 71,756 | 3,638,152 | 2.01 | 22.75 | 1,632,449 | 82,767,958 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 1,171 | 427,377 | 0.27 | 23.00 | 26,933 | 9,829,500 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 195,768 | 2,784,279 | 7.56 | 23.00 | 4,502,586 | 64,037,303 | |
2021-03-18 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,061 | 3,566,396 | 1.51 | 23.00 | 1,220,382 | 82,025,681 | |
2021-03-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Stock Option (Right to Buy) |
A - Award | 80,000 | 80,000 | |||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
3,372,098 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
2,484,643 | ||||||||
2021-03-08 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share |
405,344 | ||||||||
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -152,127 | 534,847 | -22.14 | 5.37 | -816,709 | 2,871,380 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -892,467 | 3,279,831 | -21.39 | 5.37 | -4,791,298 | 17,608,101 | |
2021-02-16 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,215,491 | 4,448,421 | -21.46 | 5.37 | -6,525,485 | 23,881,793 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -4,325 | 233,150 | -1.82 | 18.00 | -77,850 | 4,196,700 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -16,850 | 1,188,131 | -1.40 | 18.00 | -303,300 | 21,386,358 | |
2021-02-04 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -25,234 | 1,642,186 | -1.51 | 18.00 | -454,212 | 29,559,348 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -568,019 | 686,974 | -45.26 | 4.14 | -2,350,917 | 2,843,248 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,458,838 | 4,172,298 | -37.08 | 4.14 | -10,176,639 | 17,268,307 | |
2021-01-26 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,821,663 | 5,663,912 | -33.25 | 4.14 | -11,678,299 | 23,441,799 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 43,422 | 426,206 | 11.34 | 24.75 | 1,074,694 | 10,548,598 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 343,444 | 2,588,511 | 15.30 | 24.75 | 8,500,239 | 64,065,647 | |
2021-01-25 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 457,814 | 3,513,335 | 14.98 | 24.75 | 11,330,896 | 86,955,041 | |
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -1,757 | 6,758 | -20.63 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -9,169 | 39,693 | -18.77 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock |
C - Conversion | -11,776 | 52,145 | -18.42 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -35 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -203 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred |
C - Conversion | -273 | 0 | -100.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 97,615 | 113,152 | 628.27 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 1,944 | 15,537 | 14.30 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 509,410 | 598,624 | 571.00 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 11,278 | 89,214 | 14.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 654,215 | 771,780 | 556.47 | ||||
2020-12-28 |
|
4 | NVUS |
Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value |
C - Conversion | 15,166 | 117,565 | 14.81 | ||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,945,743 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
2,164,406 | ||||||||
2020-12-28 | 3 | CTMX |
CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share |
358,450 | ||||||||
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 45,032 | 2,245,067 | 2.05 | 16.05 | 722,764 | 36,033,325 | |
2020-12-22 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 114,968 | 3,055,521 | 3.91 | 16.05 | 1,845,236 | 49,041,112 | |
2020-12-15 |
|
4 | XOMA |
XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock |
P - Purchase | 200,000 | 200,000 | 25.00 | 5,000,000 | 5,000,000 | ||
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -25,486 | 463,244 | -5.21 | 18.00 | -458,748 | 8,338,392 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -166,194 | 2,760,185 | -5.68 | 18.00 | -2,991,492 | 49,683,330 | |
2020-12-11 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -239,274 | 3,811,271 | -5.91 | 18.00 | -4,306,932 | 68,602,878 | |
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
4,050,545 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,926,379 | ||||||||
2020-12-04 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
488,730 | ||||||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -93 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -551 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | CYTK |
CYTOKINETICS INC
Call Option |
J - Other | -740 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -73,399 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -522,403 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -760,155 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -101,784 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673,281 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -889,186 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -185,908 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -881,156 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -1,129,404 | 0 | -100.00 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 74,991 | 436,082 | 20.77 | 19.00 | 1,424,829 | 8,285,558 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 73,399 | 361,091 | 25.51 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 101,784 | 287,692 | 54.75 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 185,908 | 185,908 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 446,425 | 2,523,265 | 21.50 | 19.00 | 8,482,075 | 47,942,035 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 522,403 | 2,076,840 | 33.61 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 673,281 | 1,554,437 | 76.41 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 881,156 | 881,156 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
P - Purchase | 613,918 | 3,392,663 | 22.09 | 19.00 | 11,664,442 | 64,460,597 | |
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 760,155 | 2,778,745 | 37.66 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 889,186 | 2,018,590 | 78.73 | ||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value |
C - Conversion | 1,129,404 | 1,129,404 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-20 |
|
4 | OLMA |
Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) |
A - Award | 21,520 | 21,520 | |||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
3,822,766 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
2,777,320 | ||||||||
2020-11-16 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
465,924 | ||||||||
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -502,649 | 81,263 | -86.08 | 20.19 | -10,146,825 | 1,640,432 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -2,949,477 | 485,513 | -85.87 | 20.19 | -59,540,207 | 9,800,905 | |
2020-11-13 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
S - Sale | -3,941,214 | 670,695 | -85.46 | 20.19 | -79,560,105 | 13,539,119 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 86,090 | 630,453 | 15.81 | 2.60 | 223,834 | 1,639,178 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 506,155 | 3,712,350 | 15.79 | 2.60 | 1,316,003 | 9,652,110 | |
2020-11-06 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 674,492 | 4,980,812 | 15.66 | 2.60 | 1,753,679 | 12,950,111 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,334 | 583,912 | 0.40 | 4.98 | 11,633 | 2,910,217 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,436 | 3,434,990 | 0.30 | 4.98 | 52,013 | 17,119,990 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 17,230 | 4,611,909 | 0.37 | 4.98 | 85,874 | 22,985,754 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,355 | 581,578 | 2.71 | 4.88 | 74,997 | 2,840,543 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 143,403 | 3,424,554 | 4.37 | 4.88 | 700,409 | 16,726,207 | |
2020-11-06 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 257,804 | 4,594,679 | 5.94 | 4.88 | 1,259,166 | 22,441,331 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,472 | 544,363 | 2.93 | 2.75 | 42,548 | 1,496,998 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 250,755 | 3,206,195 | 8.48 | 2.75 | 689,576 | 8,817,036 | |
2020-11-03 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 666,385 | 4,306,320 | 18.31 | 2.75 | 1,832,559 | 11,842,380 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 25,107 | 566,223 | 4.64 | 5.04 | 126,414 | 2,850,933 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,352 | 3,281,151 | 5.21 | 5.04 | 817,442 | 16,520,595 | |
2020-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 157,782 | 4,336,875 | 3.78 | 5.04 | 794,432 | 21,836,166 | |
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
102,400 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
77,936 | ||||||||
2020-10-05 | 3 | NVUS |
Novus Therapeutics, Inc.
Common Stock |
13,595 | ||||||||
2020-09-24 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32 | 541,116 | 0.01 | 3.80 | 122 | 2,055,537 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,201 | 1,750,704 | 0.41 | 18.20 | 131,057 | 31,862,463 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,888 | 2,040,124 | 0.49 | 18.20 | 179,960 | 37,129,849 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,991 | 1,743,503 | 0.29 | 18.45 | 92,062 | 32,160,133 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,960 | 2,030,236 | 0.34 | 18.45 | 128,382 | 37,449,124 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,069 | 1,738,512 | 0.58 | 18.39 | 185,120 | 31,962,717 | |
2020-09-23 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 12,259 | 2,023,276 | 0.61 | 18.39 | 225,383 | 37,198,132 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 10,258 | 382,784 | 2.75 | 11.75 | 120,532 | 4,497,712 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 58,745 | 2,200,035 | 2.74 | 11.75 | 690,254 | 25,850,411 | |
2020-09-17 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 77,751 | 2,940,553 | 2.72 | 11.75 | 913,574 | 34,551,498 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 12,816 | 372,526 | 3.56 | 11.10 | 142,235 | 4,134,368 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 76,374 | 2,141,290 | 3.70 | 11.10 | 847,614 | 23,764,465 | |
2020-09-14 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 100,461 | 2,862,802 | 3.64 | 11.10 | 1,114,936 | 31,771,949 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,830 | 1,728,443 | 0.22 | 18.77 | 71,891 | 32,443,912 | |
2020-09-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,907 | 2,011,017 | 0.19 | 18.77 | 73,337 | 37,747,996 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 14,339 | 359,710 | 4.15 | 11.17 | 160,167 | 4,017,961 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 82,740 | 2,064,916 | 4.17 | 11.17 | 924,206 | 23,065,112 | |
2020-09-08 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 104,827 | 2,762,341 | 3.94 | 11.17 | 1,170,918 | 30,855,349 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 7,672 | 1,724,613 | 0.45 | 18.87 | 144,741 | 32,536,721 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,900 | 2,007,110 | 0.50 | 18.87 | 186,774 | 37,866,338 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,862 | 1,716,941 | 0.40 | 18.48 | 126,814 | 31,730,100 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,143 | 1,997,210 | 0.46 | 18.48 | 168,968 | 36,909,639 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 922 | 1,710,079 | 0.05 | 19.17 | 17,676 | 32,785,464 | |
2020-09-01 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,122 | 1,988,067 | 0.06 | 19.17 | 21,511 | 38,115,022 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -180,686 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,000,955 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,336,390 | 0 | -100.00 | ||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 67,791 | 181,081 | 59.84 | 20.00 | 1,355,820 | 3,621,620 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 113,290 | 113,290 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 389,709 | 1,017,307 | 62.10 | 20.00 | 7,794,180 | 20,346,140 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 627,598 | 627,598 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
A - Award | 521,193 | 1,359,109 | 62.20 | 20.00 | 10,423,860 | 27,182,180 | |
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 837,916 | 837,916 | |||||
2020-08-25 |
|
4 | KYMR |
Kymera Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | -40,127 | 40,127 | -50.00 | ||||
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,244 | 1,709,157 | 0.13 | 19.74 | 44,308 | 33,747,305 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,443 | 1,986,945 | 0.17 | 19.74 | 67,982 | 39,232,229 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 5,179 | 1,706,913 | 0.30 | 19.31 | 100,003 | 32,959,295 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 6,504 | 1,983,502 | 0.33 | 19.31 | 125,588 | 38,300,035 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,607 | 1,701,734 | 0.09 | 19.32 | 31,050 | 32,880,224 | |
2020-08-25 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,198 | 1,976,998 | 0.47 | 19.32 | 177,720 | 38,198,765 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 158 | 3,547 | 4.66 | 35.79 | 5,655 | 126,947 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 905 | 20,390 | 4.64 | 35.79 | 32,390 | 729,758 | |
2020-08-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Call Option (Right to Buy) |
P - Purchase | 1,205 | 27,265 | 4.62 | 35.79 | 43,127 | 975,814 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,772 | 1,967,800 | 0.09 | 19.12 | 33,881 | 37,624,336 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,496 | 1,966,028 | 0.18 | 19.70 | 68,877 | 38,733,897 | |
2020-08-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 895 | 1,962,532 | 0.05 | 19.27 | 17,246 | 37,816,814 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,922 | 1,961,637 | 1.13 | 18.69 | 409,810 | 36,670,842 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 1,050 | 1,939,715 | 0.05 | 17.80 | 18,693 | 34,533,134 | |
2020-08-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,050 | 1,938,665 | 0.21 | 17.34 | 70,233 | 33,619,359 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 81 | 237,475 | 0.03 | 13.32 | 1,079 | 3,162,312 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 929 | 1,204,981 | 0.08 | 13.32 | 12,371 | 16,046,009 | |
2020-07-02 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,521 | 1,667,420 | 0.09 | 13.32 | 20,254 | 22,204,032 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1,354 | 237,394 | 0.57 | 13.93 | 18,868 | 3,308,014 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 7,854 | 1,204,052 | 0.66 | 13.93 | 109,443 | 16,778,103 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10,524 | 1,665,899 | 0.64 | 13.93 | 146,649 | 23,213,803 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 6,769 | 236,040 | 2.95 | 14.39 | 97,403 | 3,396,498 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 39,052 | 1,196,198 | 3.37 | 14.39 | 561,939 | 17,212,691 | |
2020-06-22 |
|
4 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 52,443 | 1,655,375 | 3.27 | 14.39 | 754,629 | 23,820,019 | |
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,592,281 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
4,146,495 | ||||||||
2020-06-22 | 3 | IDYA |
IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value |
3,218,620 | ||||||||
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 6,967 | 345,371 | 2.06 | 15.20 | 105,898 | 5,249,639 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 33,321 | 1,982,176 | 1.71 | 15.20 | 506,479 | 30,129,075 | |
2020-06-10 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 46,966 | 2,657,514 | 1.80 | 15.20 | 713,883 | 40,394,213 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 94,101 | 338,404 | 38.52 | 14.00 | 1,317,414 | 4,737,656 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 561,966 | 1,948,855 | 40.52 | 14.00 | 7,867,524 | 27,283,970 | |
2020-06-03 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 806,443 | 2,610,548 | 44.70 | 14.00 | 11,290,202 | 36,547,672 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -192,250 | 480,432 | -28.58 | 6.00 | -1,153,500 | 2,882,592 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,064,332 | 2,766,561 | -27.78 | 6.00 | -6,385,992 | 16,599,366 | |
2020-05-26 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1,027,016 | 3,712,340 | -21.67 | 6.00 | -6,162,096 | 22,274,040 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,476 | 541,084 | 0.83 | 4.10 | 18,352 | 2,218,444 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,810 | 3,118,799 | 1.29 | 4.10 | 163,221 | 12,787,076 | |
2020-05-18 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 249,301 | 4,179,093 | 6.34 | 4.10 | 1,022,134 | 17,134,281 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -597 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
C - Conversion | -656 | 0 | -100.00 | ||||
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 596,813 | 1,700,127 | 54.09 | 13.00 | 7,758,569 | 22,101,651 | |
2020-04-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
C - Conversion | 655,959 | 1,934,615 | 51.30 | 13.00 | 8,527,467 | 25,149,995 | |
2020-03-27 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,264 | 1,278,656 | 0.65 | 17.20 | 142,129 | 21,991,093 | |
2020-03-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,439 | 1,270,392 | 0.35 | 14.52 | 64,475 | 18,451,936 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,113 | 1,265,953 | 0.64 | 15.73 | 127,648 | 19,918,125 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,164 | 1,257,840 | 0.81 | 15.73 | 159,916 | 19,790,351 | |
2020-03-17 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 100,000 | 1,247,676 | 8.71 | 18.34 | 1,834,090 | 22,883,501 | |
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 12 | 12 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 87 | 191 | 83.65 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 841 | 1,250 | 205.62 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
P - Purchase | 981 | 1,594 | 160.03 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 104 | 104 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -104 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 409 | 409 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -409 | 0 | -100.00 | ||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series X Convertible Preferred Stock |
X - Other | 613 | 613 | |||||
2020-03-04 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Subscription Rights (right to buy) |
X - Other | -613 | 0 | -100.00 | ||||
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -74,893 | 424,419 | -15.00 | 15.79 | -1,182,321 | 6,700,218 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -510,793 | 2,350,829 | -17.85 | 15.79 | -8,063,787 | 37,112,067 | |
2020-02-18 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
S - Sale | -486,344 | 3,131,432 | -13.44 | 15.79 | -7,677,815 | 49,435,291 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 19,727 | 244,303 | 8.78 | 16.15 | 318,591 | 3,945,493 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 112,561 | 1,386,889 | 8.83 | 16.15 | 1,817,860 | 22,398,257 | |
2020-01-21 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 146,442 | 1,804,105 | 8.83 | 16.15 | 2,365,038 | 29,136,296 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 5,406 | 224,576 | 2.47 | 14.98 | 80,973 | 3,363,789 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 25,108 | 1,274,328 | 2.01 | 14.98 | 376,078 | 19,087,395 | |
2020-01-15 |
|
4 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
P - Purchase | 53,448 | 1,657,663 | 3.33 | 14.98 | 800,566 | 24,829,139 | |
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,676,820 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
4,321,825 | ||||||||
2020-01-13 | 3 | MRUS |
Merus N.V.
Common Shares, (euro)0.09 nominal value per share |
3,291,775 | ||||||||
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 32,606 | 536,608 | 6.47 | 4.05 | 132,054 | 2,173,262 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 201,096 | 3,078,989 | 6.99 | 4.05 | 814,439 | 12,469,905 | |
2019-12-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 281,318 | 3,929,792 | 7.71 | 4.05 | 1,139,338 | 15,915,658 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 165,961 | 1,103,314 | 17.71 | 22.00 | 3,651,142 | 24,272,908 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 207,234 | 1,147,676 | 22.04 | 22.00 | 4,559,148 | 25,248,872 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -35,888 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -190,899 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Subscription Rights (right to buy) |
X - Other | -245,481 | 0 | -100.00 | ||||
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 35,888 | 159,537 | 29.02 | 22.00 | 789,536 | 3,509,814 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 190,899 | 937,353 | 25.57 | 22.00 | 4,199,778 | 20,621,766 | |
2019-12-20 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
X - Other | 245,481 | 940,442 | 35.32 | 22.00 | 5,400,582 | 20,689,724 | |
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
10,080,782 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
9,353,356 | ||||||||
2019-12-12 | 3 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
7,112,414 | ||||||||
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 8,506 | 499,312 | 1.73 | 9.52 | 80,935 | 4,750,954 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 49,804 | 2,861,622 | 1.77 | 9.52 | 473,885 | 27,228,333 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 60,103 | 3,617,776 | 1.69 | 9.52 | 571,880 | 34,423,139 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 15,030 | 490,806 | 3.16 | 9.40 | 141,282 | 4,613,576 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 95,100 | 2,811,818 | 3.50 | 9.40 | 893,940 | 26,431,089 | |
2019-12-12 |
|
4 | CYTK |
CYTOKINETICS INC
Common Stock, $0.001 par value |
P - Purchase | 113,529 | 3,557,673 | 3.30 | 9.40 | 1,067,173 | 33,442,126 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,397 | 504,002 | 0.48 | 4.02 | 9,630 | 2,024,828 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,729 | 2,877,893 | 0.66 | 4.02 | 75,244 | 11,561,935 | |
2019-12-11 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 113,874 | 3,648,474 | 3.22 | 4.02 | 457,489 | 14,657,744 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,857 | 501,605 | 19.50 | 3.40 | 278,322 | 1,705,507 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 462,056 | 2,859,164 | 19.28 | 3.40 | 1,571,037 | 9,721,444 | |
2019-11-26 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 576,097 | 3,534,600 | 19.47 | 3.40 | 1,958,787 | 12,017,993 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 14,151 | 672,682 | 2.15 | 3.91 | 55,353 | 2,631,263 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79,285 | 3,830,893 | 2.11 | 3.91 | 310,131 | 14,984,921 | |
2019-11-22 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98,518 | 4,739,356 | 2.12 | 3.91 | 385,363 | 18,538,465 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 11,105 | 658,531 | 1.72 | 3.37 | 37,424 | 2,219,249 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 45,888 | 3,751,608 | 1.24 | 3.37 | 154,643 | 12,642,919 | |
2019-11-18 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 71,495 | 4,640,838 | 1.56 | 3.37 | 240,938 | 15,639,624 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 70,921 | 419,748 | 20.33 | 4.00 | 283,684 | 1,678,992 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 400,470 | 2,397,108 | 20.06 | 4.00 | 1,601,880 | 9,588,432 | |
2019-11-07 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 496,721 | 2,958,503 | 20.18 | 4.00 | 1,986,884 | 11,834,012 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 57,868 | 647,426 | 9.82 | 2.70 | 156,244 | 1,748,050 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 331,048 | 3,705,720 | 9.81 | 2.70 | 893,830 | 10,005,444 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 408,592 | 4,569,343 | 9.82 | 2.70 | 1,103,198 | 12,337,226 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 116,552 | 589,558 | 24.64 | 2.60 | 303,035 | 1,532,851 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 610,052 | 3,374,672 | 22.07 | 2.60 | 1,586,135 | 8,774,147 | |
2019-10-31 |
|
4 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 872,373 | 4,160,751 | 26.53 | 2.60 | 2,268,170 | 10,817,953 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 504 | 348,827 | 0.14 | 3.85 | 1,940 | 1,342,844 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,913 | 1,996,638 | 0.15 | 3.85 | 11,214 | 7,686,258 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,416 | 2,461,782 | 0.14 | 3.85 | 13,150 | 9,476,876 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,456 | 348,323 | 0.42 | 3.89 | 5,667 | 1,355,708 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,236 | 1,993,725 | 0.41 | 3.89 | 32,055 | 7,759,777 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 10,389 | 2,458,366 | 0.42 | 3.89 | 40,435 | 9,568,206 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 240 | 346,867 | 0.07 | 3.90 | 935 | 1,351,706 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,133 | 1,985,489 | 0.06 | 3.90 | 4,415 | 7,737,252 | |
2019-10-31 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,027 | 2,447,977 | 0.04 | 3.90 | 4,002 | 9,539,522 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,155 | 346,627 | 0.63 | 3.75 | 8,075 | 1,298,915 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 12,899 | 1,984,356 | 0.65 | 3.75 | 48,336 | 7,435,977 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,728 | 2,446,950 | 0.65 | 3.75 | 58,938 | 9,169,456 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,629 | 344,472 | 0.48 | 3.74 | 6,100 | 1,289,944 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 57,723 | 1,971,457 | 3.02 | 3.74 | 216,155 | 7,382,515 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 76,036 | 2,431,222 | 3.23 | 3.74 | 284,732 | 9,104,197 | |
2019-10-25 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,200 | 2,355,186 | 0.14 | 3.75 | 11,986 | 8,821,349 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,689 | 342,843 | 1.39 | 3.68 | 17,270 | 1,262,691 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,716 | 1,913,734 | 1.31 | 3.68 | 91,029 | 7,048,282 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 31,007 | 2,351,986 | 1.34 | 3.68 | 114,199 | 8,662,364 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 24,425 | 338,154 | 7.79 | 3.75 | 91,594 | 1,268,078 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 14,242 | 313,729 | 4.76 | 3.75 | 53,382 | 1,175,919 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 138,609 | 1,889,018 | 7.92 | 3.75 | 519,784 | 7,083,818 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 80,821 | 1,750,409 | 4.84 | 3.75 | 302,933 | 6,560,883 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 168,640 | 2,320,979 | 7.84 | 3.75 | 632,400 | 8,703,671 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 98,333 | 2,152,339 | 4.79 | 3.75 | 368,572 | 8,067,397 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 991 | 299,487 | 0.33 | 3.74 | 3,704 | 1,119,333 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,314 | 1,669,588 | 0.44 | 3.74 | 27,336 | 6,240,085 | |
2019-10-08 |
|
4 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
P - Purchase | 7,695 | 2,054,006 | 0.38 | 3.74 | 28,760 | 7,676,847 | |
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
6,053,392 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
5,669,355 | ||||||||
2019-10-02 | 3 | FPRX |
FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value |
4,305,577 | ||||||||
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -1,128 | 314,139 | -0.36 | 4.50 | -5,075 | 1,413,437 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -25,720 | 2,233,074 | -1.14 | 4.50 | -115,725 | 10,047,493 | |
2019-09-10 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -23,152 | 2,385,055 | -0.96 | 4.50 | -104,170 | 10,731,316 | |
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,390,475 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,241,062 | ||||||||
2019-09-10 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,297,535 | ||||||||
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 124,956 | 528,891 | 30.93 | 3.18 | 397,610 | 1,682,931 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 689,834 | 2,955,440 | 30.45 | 3.18 | 2,195,052 | 9,404,210 | |
2019-09-09 |
|
4 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
P - Purchase | 853,956 | 3,639,935 | 30.65 | 3.18 | 2,717,288 | 11,582,273 | |
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
8,241,499 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
7,721,126 | ||||||||
2019-08-26 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value |
5,859,455 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,814,382 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
9,290,624 | ||||||||
2019-07-01 | 3 | CALA |
Calithera Biosciences, Inc.
Common Stock, $0.0001 par value |
6,999,010 | ||||||||
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -29,450 | 169,589 | -14.80 | 10.70 | -315,230 | 1,815,264 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -158,583 | 952,859 | -14.27 | 10.70 | -1,697,457 | 10,199,307 | |
2019-06-12 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -198,256 | 1,178,904 | -14.40 | 10.70 | -2,122,112 | 12,618,871 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 13,816 | 746,454 | 1.89 | 14.74 | 203,664 | 11,003,628 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 3,797 | 732,638 | 0.52 | 14.36 | 54,526 | 10,520,975 | |
2019-05-14 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,300 | 728,841 | 1.43 | 14.57 | 150,037 | 10,616,808 | |
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
4,064,801 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
3,799,083 | ||||||||
2019-04-02 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
2,886,680 | ||||||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 284 | 284 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,143 | 2,143 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value |
J - Other | 2,573 | 2,573 | |||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -284,000 | 141,346 | -66.77 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,143,000 | 772,324 | -73.51 | ||||
2019-02-01 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
J - Other | -2,573,000 | 978,200 | -72.45 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 372 | 597 | 165.47 | 13,000.00 | 4,836,000 | 7,758,569 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 311 | 656 | 89.96 | 13,000.00 | 4,038,398 | 8,527,467 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 718,541 | 3.60 | 14.19 | 354,792 | 10,197,318 | |
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 225 | 225 | 13,000.00 | 2,922,569 | 2,922,569 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -225 | 0 | -100.00 | ||||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Series Y Convertible Preferred Stock |
X - Other | 345 | 345 | 13,000.00 | 4,489,069 | 4,489,069 | ||
2018-12-19 |
|
4 | XOMA |
XOMA Corp
Subscription Rights |
X - Other | -345 | 0 | -100.00 | ||||
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 120,539 | 6,631,136 | 1.85 | 1.20 | 144,587 | 7,954,048 | |
2018-12-17 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 54,461 | 8,485,575 | 0.65 | 1.20 | 65,326 | 10,178,447 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 24,253 | 693,541 | 3.62 | 14.41 | 349,525 | 9,995,035 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 2,810 | 669,288 | 0.42 | 14.75 | 41,448 | 9,871,998 | |
2018-12-13 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,400 | 666,478 | 1.43 | 14.50 | 136,270 | 9,661,798 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 18,081 | 657,078 | 2.83 | 14.54 | 262,972 | 9,556,608 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 32,015 | 638,997 | 5.27 | 14.77 | 472,778 | 9,436,324 | |
2018-12-10 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,927 | 606,982 | 1.83 | 14.80 | 161,698 | 8,982,120 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,171 | 596,055 | 0.70 | 14.99 | 62,515 | 8,933,672 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 806 | 591,884 | 0.14 | 14.90 | 12,009 | 8,819,072 | |
2018-12-04 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 4,823 | 591,078 | 0.82 | 14.85 | 71,615 | 8,776,681 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -89,948 | 370,391 | -19.54 | 1.83 | -164,929 | 679,149 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -382,017 | 1,942,764 | -16.43 | 1.83 | -700,466 | 3,562,252 | |
2018-12-04 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
S - Sale | -430,035 | 2,502,758 | -14.66 | 1.83 | -788,512 | 4,589,057 | |
2018-11-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 100,000 | 6,510,597 | 1.56 | 1.30 | 130,000 | 8,463,776 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,016 | 586,255 | 1.74 | 14.93 | 149,543 | 8,753,022 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 8,288 | 576,239 | 1.46 | 15.11 | 125,262 | 8,709,046 | |
2018-11-29 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 11,396 | 567,951 | 2.05 | 15.24 | 173,680 | 8,655,800 | |
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
10,443,070 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
9,807,194 | ||||||||
2018-11-26 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,317,216 | ||||||||
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 25,000 | 556,555 | 4.70 | 15.00 | 374,892 | 8,345,932 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 37,482 | 531,555 | 7.59 | 13.68 | 512,701 | 7,270,928 | |
2018-11-21 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 9,771 | 494,073 | 2.02 | 13.93 | 136,064 | 6,880,115 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 581 | 1,254,993 | 0.05 | 1.35 | 784 | 1,694,241 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 4,119 | 8,431,114 | 0.05 | 1.35 | 5,561 | 11,382,004 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 5,573 | 1,254,412 | 0.45 | 1.35 | 7,524 | 1,693,456 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 38,001 | 6,410,597 | 0.60 | 1.35 | 51,301 | 8,654,306 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 50,044 | 8,426,995 | 0.60 | 1.35 | 67,559 | 11,376,443 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,648 | 1,248,839 | 7.00 | 1.37 | 111,841 | 1,710,660 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 556,709 | 6,372,596 | 9.57 | 1.37 | 762,580 | 8,729,182 | |
2018-11-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 733,151 | 8,376,951 | 9.59 | 1.37 | 1,004,270 | 11,474,747 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 10,849 | 484,302 | 2.29 | 13.82 | 149,986 | 6,695,427 | |
2018-11-19 |
|
4 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
P - Purchase | 21,141 | 473,453 | 4.67 | 13.31 | 281,361 | 6,301,091 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 39,074 | 5,815,887 | 0.68 | 1.35 | 52,750 | 7,851,447 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,400 | 7,643,800 | 0.69 | 1.35 | 70,740 | 10,319,130 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 92,960 | 5,776,813 | 1.64 | 1.34 | 124,566 | 7,740,929 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 117,290 | 7,591,400 | 1.57 | 1.34 | 157,169 | 10,172,476 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 562,754 | 5,683,853 | 10.99 | 1.35 | 759,718 | 7,673,202 | |
2018-11-15 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 41,454 | 7,474,110 | 0.56 | 1.35 | 55,963 | 10,090,048 | |
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,650,706 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
8,042,694 | ||||||||
2018-11-09 | 3 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock, $0.001 par value |
6,178,252 | ||||||||
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 36,825 | 1,167,191 | 3.26 | 1.65 | 60,761 | 1,925,865 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 158,151 | 5,121,099 | 3.19 | 1.65 | 260,949 | 8,449,813 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 230,555 | 7,432,656 | 3.20 | 1.65 | 380,416 | 12,263,882 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 179,893 | 1,130,366 | 18.93 | 1.65 | 296,823 | 1,865,104 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,419,907 | 4,962,948 | 40.08 | 1.65 | 2,342,847 | 8,188,864 | |
2018-06-21 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,916,760 | 7,202,101 | 36.27 | 1.65 | 3,162,654 | 11,883,467 | |
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 188,746 | 188,746 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 705,863 | 705,863 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Warrants |
J - Other | 1,105,391 | 1,105,391 | |||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -188,746 | 85,038 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -705,863 | 318,021 | -68.94 | ||||
2018-06-20 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
J - Other | -1,105,391 | 498,025 | -68.94 | ||||
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -175,813 | 771,305 | -18.56 | 5.00 | -879,083 | 3,856,602 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -312,266 | 3,186,044 | -8.93 | 5.00 | -1,561,361 | 15,930,539 | |
2018-06-01 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -547,860 | 4,682,669 | -10.47 | 5.00 | -2,739,355 | 23,413,813 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -217,256 | 947,118 | -18.66 | 3.10 | -673,494 | 2,936,066 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -808,449 | 3,498,310 | -18.77 | 3.10 | -2,506,192 | 10,844,761 | |
2018-04-20 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,204,668 | 5,230,529 | -18.72 | 3.10 | -3,734,471 | 16,214,640 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 97,453 | 950,473 | 11.42 | 2.00 | 194,906 | 1,900,946 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 365,682 | 3,543,041 | 11.51 | 2.00 | 731,364 | 7,086,082 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 546,865 | 5,285,341 | 11.54 | 2.00 | 1,093,730 | 10,570,682 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 62,437 | 853,020 | 7.90 | 1.90 | 118,630 | 1,620,738 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 208,872 | 3,177,359 | 7.04 | 1.90 | 396,857 | 6,036,982 | |
2018-04-11 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 228,691 | 4,738,476 | 5.07 | 1.90 | 434,513 | 9,003,104 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -214,336 | 1,164,374 | -15.55 | 2.90 | -621,574 | 3,376,685 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -817,611 | 4,306,759 | -15.96 | 2.90 | -2,371,072 | 12,489,601 | |
2018-04-06 |
|
4 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
S - Sale | -1,269,634 | 6,435,197 | -16.48 | 2.90 | -3,681,939 | 18,662,071 | |
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 238,000 | 238,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 861,000 | 861,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares |
J - Other | 1,338,000 | 1,338,000 | |||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -238,000 | 59,464 | -80.01 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -861,000 | 216,694 | -79.89 | ||||
2018-03-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Shares, no par value per share |
J - Other | -1,338,000 | 336,468 | -79.91 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 2,280 | 2,280 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 1,024 | 1,024 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 3,640 | 3,640 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series O Preferred Stock |
A - Award | 5,631 | 5,631 | |||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -49 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -48 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -197 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N Preferred Stock |
D - Sale to Issuer | -281 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 699,225 | 1,295,582 | 117.25 | 3.00 | 2,097,675 | 3,886,746 | |
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 483,708 | 483,708 | 3.00 | 1,451,124 | 1,451,124 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 2,109,280 | 2,109,280 | 3.00 | 6,327,840 | 6,327,840 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
P - Purchase | 3,041,120 | 3,041,120 | 3.00 | 9,123,360 | 9,123,360 | ||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -1,487,294 | 596,357 | -71.38 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -651,074 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -2,295,083 | 0 | -100.00 | ||||
2018-02-12 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, par value $0.001 |
D - Sale to Issuer | -3,566,549 | 0 | -100.00 | ||||
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -169,292 | 122,496 | -58.02 | 26.65 | -4,511,632 | 3,264,518 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -445,615 | 632,642 | -41.33 | 26.65 | -11,875,640 | 16,859,909 | |
2017-12-21 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
S - Sale | -667,949 | 951,300 | -41.25 | 26.65 | -17,800,841 | 25,352,145 | |
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
4,504,500 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,924,968 | ||||||||
2017-12-08 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share |
3,174,868 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
17,248,837 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
15,027,176 | ||||||||
2017-11-27 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share |
12,158,047 | ||||||||
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 34,632 | 291,788 | 13.47 | 15.84 | 548,484 | 4,621,192 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 135,206 | 1,078,257 | 14.34 | 15.84 | 2,141,325 | 17,076,895 | |
2017-10-23 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 162,078 | 1,619,249 | 11.12 | 15.84 | 2,566,910 | 25,644,856 | |
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
21,912,742 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
19,332,281 | ||||||||
2017-10-20 | 3 | ARQL |
ARQULE INC
Common Stock, $0.01 par value per share |
15,586,621 | ||||||||
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 63,042 | 790,583 | 8.67 | 1.28 | 80,946 | 1,015,109 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 235,326 | 2,968,487 | 8.61 | 1.28 | 302,159 | 3,811,537 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 355,081 | 4,509,785 | 8.55 | 1.28 | 455,924 | 5,790,564 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 28,918 | 727,541 | 4.14 | 1.24 | 35,714 | 898,513 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 394,078 | 2,733,161 | 16.85 | 1.24 | 486,686 | 3,375,454 | |
2017-10-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 523,601 | 4,154,704 | 14.42 | 1.24 | 646,647 | 5,131,059 | |
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
4,114,549 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
3,600,429 | ||||||||
2017-09-29 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share |
2,914,534 | ||||||||
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 7,429 | 1,077,694 | 0.69 | 2.41 | 17,920 | 2,599,613 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 11,429 | 1,674,468 | 0.69 | 2.41 | 27,569 | 4,039,152 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 13,337 | 1,070,265 | 1.26 | 2.70 | 36,058 | 2,893,568 | |
2017-08-16 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 28,007 | 1,663,039 | 1.71 | 2.70 | 75,720 | 4,496,192 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -105,713 | 890,487 | -10.61 | 0.06 | -6,343 | 53,429 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -242,236 | 1,377,652 | -14.95 | 0.06 | -14,534 | 82,659 | |
2017-07-18 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
S - Sale | -3,993,637 | 0 | -100.00 | 0.06 | -239,618 | ||
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 3.04 | 25,795 | 903,130 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 3.04 | 91,599 | 3,208,939 | |
2017-06-30 |
|
4/A | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 3.04 | 142,074 | 4,964,121 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 8,496 | 297,464 | 2.94 | 4.00 | 33,984 | 1,189,856 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 30,170 | 1,056,928 | 2.94 | 4.00 | 120,680 | 4,227,712 | |
2017-06-29 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 46,795 | 1,635,032 | 2.95 | 4.00 | 187,180 | 6,540,128 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 854 | 288,968 | 0.30 | 4.00 | 3,416 | 1,155,872 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 2,884 | 1,026,758 | 0.28 | 4.00 | 11,536 | 4,107,032 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,525 | 1,588,237 | 0.29 | 4.00 | 18,100 | 6,352,948 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,362 | 288,114 | 0.47 | 4.00 | 5,448 | 1,152,456 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 4,406 | 1,023,874 | 0.43 | 4.00 | 17,624 | 4,095,496 | |
2017-06-23 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,380 | 1,583,712 | 0.40 | 4.00 | 25,520 | 6,334,848 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,715 | 201,811 | 0.86 | 2.25 | 3,859 | 454,075 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,359 | 717,089 | 0.89 | 2.25 | 14,308 | 1,613,450 | |
2017-06-22 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 9,732 | 1,109,258 | 0.89 | 2.25 | 21,897 | 2,495,830 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 357 | 286,752 | 0.12 | 3.85 | 1,374 | 1,103,995 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,271 | 1,019,468 | 0.12 | 3.85 | 4,893 | 3,924,952 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,967 | 1,577,332 | 0.12 | 3.85 | 7,573 | 6,072,728 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,064 | 286,395 | 0.37 | 3.85 | 4,096 | 1,102,621 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,873 | 1,018,197 | 0.38 | 3.85 | 14,911 | 3,920,058 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,097 | 1,575,365 | 0.39 | 3.85 | 23,473 | 6,065,155 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 1,160 | 285,331 | 0.41 | 3.84 | 4,451 | 1,094,815 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 3,845 | 1,014,324 | 0.38 | 3.84 | 14,753 | 3,891,961 | |
2017-06-19 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 6,774 | 1,569,268 | 0.43 | 3.84 | 25,992 | 6,021,281 | |
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -536 | 49 | -91.62 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -513 | 48 | -91.44 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -2,115 | 197 | -91.48 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
C - Conversion | -3,011 | 281 | -91.46 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 585 | 585 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 561 | 561 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 2,312 | 2,312 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share |
P - Purchase | 3,292 | 3,292 | |||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 357,333 | 2,083,651 | 20.70 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 342,000 | 651,074 | 110.65 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 1,410,000 | 2,295,083 | 159.31 | ||||
2017-06-14 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
C - Conversion | 2,007,333 | 3,566,549 | 128.74 | ||||
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 20,594 | 284,171 | 7.81 | 3.85 | 79,312 | 1,094,399 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 73,749 | 1,010,479 | 7.87 | 3.85 | 284,022 | 3,891,557 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 113,446 | 1,562,494 | 7.83 | 3.85 | 436,903 | 6,017,477 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 913 | 263,577 | 0.35 | 3.75 | 3,424 | 988,414 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 53,260 | 936,730 | 6.03 | 3.75 | 199,725 | 3,512,738 | |
2017-06-08 |
|
4 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
P - Purchase | 96,736 | 1,449,048 | 7.15 | 3.75 | 362,760 | 5,433,930 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,673 | 200,096 | 1.87 | 2.28 | 8,379 | 456,479 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 13,046 | 710,730 | 1.87 | 2.28 | 29,762 | 1,621,388 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 20,181 | 1,099,526 | 1.87 | 2.28 | 46,039 | 2,508,349 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,920 | 196,423 | 2.04 | 2.29 | 8,979 | 449,927 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 12,624 | 697,684 | 1.84 | 2.29 | 28,917 | 1,598,115 | |
2017-06-07 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 19,206 | 1,079,345 | 1.81 | 2.29 | 43,993 | 2,472,348 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,727 | 192,503 | 1.44 | 2.25 | 6,128 | 432,554 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,023 | 685,060 | 1.48 | 2.25 | 22,522 | 1,539,330 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 15,350 | 1,060,139 | 1.47 | 2.25 | 34,491 | 2,382,132 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,805 | 189,776 | 0.96 | 2.30 | 4,144 | 435,669 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,903 | 675,037 | 1.03 | 2.30 | 15,847 | 1,549,682 | |
2017-06-01 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,192 | 1,044,789 | 0.99 | 2.30 | 23,398 | 2,398,522 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 1,124 | 187,971 | 0.60 | 2.30 | 2,585 | 432,333 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 4,223 | 668,134 | 0.64 | 2.30 | 9,713 | 1,536,708 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,253 | 1,034,597 | 0.61 | 2.30 | 14,382 | 2,379,573 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,909 | 186,847 | 1.58 | 2.30 | 6,690 | 429,711 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 10,541 | 663,911 | 1.61 | 2.30 | 24,242 | 1,526,863 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 16,436 | 1,028,344 | 1.62 | 2.30 | 37,800 | 2,364,986 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 5,510 | 183,938 | 3.09 | 2.30 | 12,666 | 422,818 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,897 | 653,370 | 1.07 | 2.30 | 15,854 | 1,501,902 | |
2017-05-19 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 24,965 | 1,011,908 | 2.53 | 2.30 | 57,387 | 2,326,073 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 675 | 178,428 | 0.38 | 2.34 | 1,581 | 418,039 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 2,565 | 646,473 | 0.40 | 2.34 | 6,010 | 1,514,622 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,794 | 986,943 | 0.39 | 2.34 | 8,889 | 2,312,309 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 6,217 | 177,753 | 3.62 | 2.35 | 14,583 | 416,955 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 22,092 | 643,908 | 3.55 | 2.35 | 51,821 | 1,510,415 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 33,691 | 983,149 | 3.55 | 2.35 | 79,029 | 2,306,173 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 3,929 | 171,536 | 2.34 | 2.29 | 8,989 | 392,457 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 14,274 | 621,816 | 2.35 | 2.29 | 32,657 | 1,422,653 | |
2017-05-11 |
|
4 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value |
P - Purchase | 21,797 | 949,458 | 2.35 | 2.29 | 49,869 | 2,172,265 | |
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,630,471 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
2,310,352 | ||||||||
2017-05-11 | 3 | NVLS |
Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share |
1,870,417 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,665,288 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
4,098,367 | ||||||||
2017-05-11 | 3 | GLYC |
GLYCOMIMETICS INC
Common Stock, $0.001 par value per share |
3,319,001 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
2,197,761 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,955,112 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,626,449 | ||||||||
2017-02-21 | 3 | XOMA |
XOMA Corp
Common Stock, $0.0075 par value per share |
1,734,678 | ||||||||
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 3,234 | 2,339,083 | 0.14 | 1.34 | 4,333 | 3,133,669 | |
2017-01-05 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,145 | 3,631,103 | 0.03 | 1.34 | 1,534 | 4,864,589 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 1,205 | 2,335,849 | 0.05 | 1.34 | 1,614 | 3,129,103 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,348 | 3,629,958 | 0.06 | 1.34 | 3,145 | 4,862,692 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 77,076 | 698,623 | 12.40 | 1.34 | 102,943 | 933,081 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 260,046 | 2,334,644 | 12.53 | 1.34 | 347,317 | 3,118,151 | |
2016-12-30 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 401,726 | 3,627,610 | 12.45 | 1.34 | 536,545 | 4,845,036 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,244 | 621,547 | 0.36 | 1.35 | 3,040 | 842,134 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 8,111 | 2,074,598 | 0.39 | 1.35 | 10,990 | 2,810,873 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 11,646 | 3,225,884 | 0.36 | 1.35 | 15,779 | 4,370,750 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 21,021 | 619,303 | 3.51 | 1.36 | 28,555 | 841,261 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 69,041 | 2,066,487 | 3.46 | 1.36 | 93,785 | 2,807,116 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 108,202 | 3,214,238 | 3.48 | 1.36 | 146,982 | 4,366,221 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 47,812 | 598,282 | 8.69 | 1.28 | 61,199 | 765,801 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 150,451 | 1,997,446 | 8.15 | 1.28 | 192,577 | 2,556,731 | |
2016-12-20 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 236,393 | 3,106,036 | 8.24 | 1.28 | 302,583 | 3,975,726 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 2,916 | 550,470 | 0.53 | 1.19 | 3,470 | 655,114 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 18,586 | 1,846,995 | 1.02 | 1.19 | 22,119 | 2,198,109 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 30,998 | 2,869,643 | 1.09 | 1.19 | 36,891 | 3,415,162 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 15,161 | 547,554 | 2.85 | 1.18 | 17,958 | 648,578 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 52,457 | 1,828,409 | 2.95 | 1.18 | 62,135 | 2,165,750 | |
2016-12-02 |
|
4 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
P - Purchase | 81,276 | 2,838,645 | 2.95 | 1.18 | 96,271 | 3,362,375 | |
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
7,823,083 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
6,841,666 | ||||||||
2016-12-02 | 3 | INFI |
INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value |
5,598,107 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,850,758 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
3,381,916 | ||||||||
2016-09-12 | 3 | XENE |
Xenon Pharmaceuticals Inc.
Common Stock, no par value per share |
2,761,110 | ||||||||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 6,197 | 6,197 | 800.00 | 4,957,600 | 4,957,600 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 1,029 | 1,029 | 800.00 | 823,200 | 823,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 4,519 | 4,519 | 800.00 | 3,615,200 | 3,615,200 | ||
2016-06-27 |
|
4 | ONTY |
Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock |
A - Award | 5,505 | 5,505 | 800.00 | 4,404,000 | 4,404,000 | ||
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 58,613 | 17,263,200 | 0.34 | 1.22 | 71,338 | 21,011,041 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 32,571 | 3,090,744 | 1.07 | 1.22 | 39,642 | 3,761,745 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 90,049 | 8,850,836 | 1.03 | 1.22 | 109,599 | 10,772,352 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 186,314 | 15,592,160 | 1.21 | 1.22 | 226,763 | 18,977,218 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 8,091 | 17,204,587 | 0.05 | 1.22 | 9,848 | 20,939,703 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 29,655 | 3,058,173 | 0.98 | 1.22 | 36,093 | 3,722,102 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 87,747 | 8,760,787 | 1.01 | 1.22 | 106,797 | 10,662,754 | |
2016-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
P - Purchase | 508,287 | 15,405,846 | 3.41 | 1.22 | 618,636 | 18,750,455 | |
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
23,547,788 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
21,842,395 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
19,541,857 | ||||||||
2015-12-22 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, no par value per share |
29,064,800 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
58,693,172 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
52,468,653 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
46,824,131 | ||||||||
2015-12-14 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock, no par value per share |
60,992,109 | ||||||||
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
J - Other | -2,384,577 | 0 | -100.00 | ||||
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -287,000 | 2,384,577 | -10.74 | 7.00 | -2,009,057 | 16,692,516 | |
2015-11-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -73,000 | 2,671,577 | -2.66 | 6.98 | -509,343 | 18,640,394 | |
2015-11-02 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -50,000 | 2,744,577 | -1.79 | 6.97 | -348,515 | 19,130,525 | |
2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -31,000 | 2,794,577 | -1.10 | 9.01 | -279,229 | 25,171,873 | |
2015-06-11 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
S - Sale | -924,700 | 2,825,577 | -24.66 | 9.00 | -8,322,392 | 25,430,476 | |
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 1,400 | 1,400 | |||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Preferred Stock, $0.0001 per share |
J - Other | 2,600 | 2,600 | |||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -1,400,000 | 1,898,293 | -42.45 | ||||
2015-02-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -2,600,000 | 3,762,683 | -40.86 | ||||
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 55,197 | 3,298,293 | 1.70 | 1.73 | 95,662 | 5,716,272 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 98,298 | 6,362,683 | 1.57 | 1.73 | 170,360 | 11,027,166 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 79,434 | 3,243,096 | 2.51 | 1.88 | 149,249 | 6,093,453 | |
2014-12-17 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
P - Purchase | 145,515 | 6,264,385 | 2.38 | 1.88 | 273,408 | 11,770,153 | |
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
15,401,402 | ||||||||
2014-12-17 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
12,446,194 | ||||||||
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -242,814 | 1,223,484 | -16.56 | 1.59 | -386,074 | 1,945,340 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Warrants |
J - Other | -407,136 | 2,288,698 | -15.10 | 1.59 | -647,346 | 3,639,030 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -258,230 | 2,412,290 | -9.67 | 3.24 | -836,665 | 7,815,820 | |
2014-07-16 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
J - Other | -296,008 | 4,512,523 | -6.16 | 3.24 | -959,066 | 14,620,575 | |
2014-07-10 |
|
4 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
J - Other | -494,092 | 7,058,997 | -6.54 | 4.56 | -2,253,060 | 32,189,026 | |
2014-07-03 |
|
4 | CAPS |
Capstone Therapeutics Corp.
Common Stock, $0.0005 par value |
J - Other | -616,563 | 3,993,637 | -13.37 | 0.30 | -184,969 | 1,198,091 | |
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
16,369,219 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
14,974,663 | ||||||||
2014-07-03 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
20,518,746 | ||||||||
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10,203 | 130,175 | -7.27 | 69.95 | -713,734 | 9,106,171 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,019 | 230,125 | -7.26 | 69.95 | -1,260,489 | 16,098,003 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,306 | 140,378 | -11.54 | 70.17 | -1,284,483 | 9,849,945 | |
2014-03-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -31,698 | 248,144 | -11.33 | 70.17 | -2,224,163 | 17,411,594 | |
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 2,632 | 2,632 | |||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Preferred Stock, $0.001 per share |
J - Other | 4,577 | 4,577 | |||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -526,436 | 1,121,221 | -31.95 | ||||
2014-03-25 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock, $0.001 par value |
J - Other | -915,345 | 1,979,670 | -31.62 | ||||
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -200,827 | 2,494,521 | -7.45 | 1.09 | -218,901 | 2,719,028 | |
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33,610 | 438,127 | -7.12 | 1.09 | -36,635 | 477,558 | |
2014-03-03 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -59,388 | 772,480 | -7.14 | 1.09 | -64,733 | 842,003 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -33,236 | 2,695,348 | -1.22 | 1.11 | -36,869 | 2,989,950 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -4,416 | 471,737 | -0.93 | 1.11 | -4,899 | 523,298 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -7,745 | 831,868 | -0.92 | 1.11 | -8,592 | 922,791 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -151,535 | 2,728,584 | -5.26 | 1.12 | -169,659 | 3,054,923 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -25,060 | 476,153 | -5.00 | 1.12 | -28,057 | 533,101 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -44,147 | 839,613 | -5.00 | 1.12 | -49,427 | 940,031 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -191,804 | 2,880,119 | -6.24 | 1.16 | -222,838 | 3,346,122 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -29,710 | 501,213 | -5.60 | 1.16 | -34,517 | 582,309 | |
2014-02-26 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -52,528 | 883,760 | -5.61 | 1.16 | -61,027 | 1,026,752 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5,359 | 79,390 | -6.32 | 73.05 | -391,464 | 5,799,273 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -112,369 | 1,685,344 | -6.25 | 73.05 | -8,208,319 | 123,110,840 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -10,557 | 158,684 | -6.24 | 73.05 | -771,167 | 11,591,533 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -18,615 | 279,842 | -6.24 | 73.05 | -1,359,787 | 20,441,870 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -2,771 | 84,749 | -3.17 | 73.03 | -202,375 | 6,189,499 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -57,370 | 1,797,713 | -3.09 | 73.03 | -4,189,920 | 131,292,913 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -5,395 | 169,241 | -3.09 | 73.03 | -394,015 | 12,360,229 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -9,464 | 298,457 | -3.07 | 73.03 | -691,187 | 21,797,300 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -14,003 | 87,520 | -13.79 | 74.66 | -1,045,409 | 6,533,902 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -153,751 | 1,855,083 | -7.65 | 74.66 | -11,478,450 | 138,493,262 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16,331 | 174,636 | -8.55 | 74.66 | -1,219,209 | 13,037,643 | |
2014-02-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value |
S - Sale | -16,915 | 307,921 | -5.21 | 74.66 | -1,262,808 | 22,988,181 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -19,077 | 3,071,923 | -0.62 | 1.11 | -21,216 | 3,416,286 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -10,470 | 530,923 | -1.93 | 1.11 | -11,644 | 590,439 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -14,059 | 936,288 | -1.48 | 1.11 | -15,635 | 1,041,246 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -110,885 | 541,393 | -17.00 | 1.18 | -130,623 | 637,761 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -122,443 | 950,347 | -11.41 | 1.18 | -144,238 | 1,119,509 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -15,622 | 652,278 | -2.34 | 1.16 | -18,139 | 757,360 | |
2014-02-19 |
|
4 | PTN |
PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share |
S - Sale | -13,410 | 1,072,790 | -1.23 | 1.16 | -15,570 | 1,245,616 | |
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
5,080,487 | ||||||||
2014-02-10 | 3 | RGDO |
Regado Biosciences Inc
Common stock, $0.001 par value |
4,222,129 | ||||||||
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 41,451 | 1,251,914 | 3.42 | 5.03 | 208,358 | 6,292,871 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 82,849 | 2,162,381 | 3.98 | 5.03 | 416,449 | 10,869,424 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 16,175 | 1,210,463 | 1.35 | 4.98 | 80,590 | 6,031,011 | |
2013-12-05 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 49,325 | 2,079,532 | 2.43 | 4.98 | 245,757 | 10,361,060 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -154,578 | 2,008,834 | -7.15 | 57.07 | -8,822,493 | 114,653,598 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -27,058 | 101,523 | -21.04 | 57.07 | -1,544,327 | 5,794,395 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -50,934 | 190,967 | -21.06 | 57.07 | -2,907,043 | 10,899,384 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -86,435 | 324,836 | -21.02 | 57.07 | -4,933,252 | 18,539,917 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -34,917 | 128,581 | -21.36 | 57.57 | -2,010,172 | 7,402,408 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -54,444 | 241,901 | -18.37 | 57.57 | -3,134,341 | 13,926,241 | |
2013-11-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -119,139 | 411,271 | -22.46 | 57.57 | -6,858,832 | 23,676,871 | |
2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -153,056 | 646,559 | -19.14 | 2.64 | -404,343 | 1,708,080 | |
2013-11-20 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
S - Sale | -331,566 | 1,123,848 | -22.78 | 2.64 | -875,931 | 2,968,982 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 8,371 | 1,194,288 | 0.71 | 4.69 | 39,235 | 5,597,628 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 11,985 | 2,030,207 | 0.59 | 4.69 | 56,174 | 9,515,580 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 74,684 | 1,185,917 | 6.72 | 4.97 | 370,978 | 5,890,806 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 35,526 | 2,018,222 | 1.79 | 4.97 | 176,468 | 10,025,114 | |
2013-11-06 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 5,500 | 1,111,233 | 0.50 | 4.90 | 26,944 | 5,443,819 | |
2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 79,360 | 2,670,520 | 3.06 | 1.78 | 141,261 | 4,753,526 | |
2013-11-05 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 49,640 | 4,808,531 | 1.04 | 1.78 | 88,359 | 8,559,185 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 25,154 | 1,105,733 | 2.33 | 4.92 | 123,775 | 5,440,980 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 45,406 | 1,982,696 | 2.34 | 4.92 | 223,429 | 9,756,252 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 44,584 | 1,080,579 | 4.30 | 4.97 | 221,373 | 5,365,399 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 79,998 | 1,937,290 | 4.31 | 4.97 | 397,214 | 9,619,226 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 50,339 | 1,035,995 | 5.11 | 5.04 | 253,693 | 5,221,104 | |
2013-11-01 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 90,744 | 1,857,292 | 5.14 | 5.04 | 457,323 | 9,360,194 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 29,564 | 985,656 | 3.09 | 5.26 | 155,445 | 5,182,481 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 53,271 | 1,766,548 | 3.11 | 5.26 | 280,094 | 9,288,333 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 401,675 | 956,092 | 72.45 | 5.35 | 2,148,961 | 5,115,092 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 30,406 | 554,417 | 5.80 | 5.31 | 161,310 | 2,941,293 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 726,626 | 1,713,277 | 73.65 | 5.35 | 3,887,449 | 9,166,032 | |
2013-10-10 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 47,812 | 986,651 | 5.09 | 5.31 | 253,652 | 5,234,381 | |
2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 38,599 | 524,011 | 7.95 | 5.49 | 212,071 | 2,879,021 | |
2013-10-07 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 70,826 | 938,839 | 8.16 | 5.49 | 389,132 | 5,158,169 | |
2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -147,806 | 296,345 | -33.28 | 44.50 | -6,577,367 | 13,187,352 | |
2013-09-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | -211,217 | 530,410 | -28.48 | 44.50 | -9,399,156 | 23,603,245 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 3,370 | 485,412 | 0.70 | 6.09 | 20,520 | 2,955,722 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 6,307 | 868,013 | 0.73 | 6.09 | 38,404 | 5,285,418 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 105,892 | 482,042 | 28.15 | 5.94 | 629,136 | 2,863,956 | |
2013-09-13 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 210,066 | 861,706 | 32.24 | 5.94 | 1,248,065 | 5,119,654 | |
2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 177,940 | 2,591,160 | 7.37 | 1.65 | 293,512 | 4,274,118 | |
2013-08-12 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 80,421 | 4,758,891 | 1.72 | 1.65 | 132,654 | 7,849,791 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 35,703 | 2,413,220 | 1.50 | 1.78 | 63,651 | 4,302,289 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 122,641 | 4,678,470 | 2.69 | 1.78 | 218,644 | 8,340,776 | |
2013-08-02 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 179,743 | 4,555,829 | 4.11 | 1.71 | 307,307 | 7,789,101 | |
2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 8,102 | 799,615 | 1.02 | 3.47 | 28,095 | 2,772,825 | |
2013-06-11 |
|
4 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock |
P - Purchase | 24,598 | 1,455,414 | 1.72 | 3.47 | 85,298 | 5,046,939 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 41,526 | 2,377,517 | 1.78 | 1.83 | 76,009 | 4,351,807 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 74,726 | 4,376,086 | 1.74 | 1.83 | 136,778 | 8,009,988 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 27,384 | 2,335,991 | 1.19 | 1.78 | 48,768 | 4,160,166 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 55,531 | 4,301,360 | 1.31 | 1.78 | 98,895 | 7,660,292 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 5,000 | 2,308,607 | 0.22 | 1.75 | 8,750 | 4,040,062 | |
2013-06-07 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
P - Purchase | 10,300 | 4,245,829 | 0.24 | 1.75 | 18,025 | 7,430,201 | |
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
4,235,529 | ||||||||
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
2,303,607 | ||||||||
2013-06-07 | 3 | ONTY |
Oncothyreon Inc.
Common Stock, $0.0001 par value |
1,298,842 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
1,430,816 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
791,513 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
6,962,123 | ||||||||
2013-05-15 | 3 | RIGL |
RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value |
513,545 | ||||||||
2013-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 39,600 | 2,163,412 | 1.86 | 19.78 | 783,181 | 42,786,448 | |
2012-12-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 5,386 | 2,123,812 | 0.25 | 18.63 | 100,365 | 39,575,962 | |
2012-12-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 50,100 | 2,118,426 | 2.42 | 17.94 | 898,959 | 38,011,553 | |
2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 217,000 | 1,713,907 | 14.50 | 4.00 | 867,935 | 6,855,114 | |
2012-11-20 |
|
4/A | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 378,000 | 2,977,919 | 14.54 | 4.00 | 1,511,887 | 11,910,783 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 26,800 | 1,523,707 | 1.79 | 5.11 | 136,902 | 7,783,552 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46,700 | 2,646,619 | 1.80 | 5.11 | 238,558 | 13,519,724 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 444,649 | 1,496,907 | 42.26 | 4.00 | 1,778,596 | 5,987,628 | |
2012-11-19 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 772,063 | 2,599,919 | 42.24 | 4.00 | 3,088,252 | 10,399,676 | |
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
790,501 | ||||||||
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
456,746 | ||||||||
2012-11-19 | 3 | ARRY |
ARRAY BIOPHARMA INC
Common Stock, $0.001 par value |
9,894,589 | ||||||||
2012-11-19 |
|
4/A | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40,000 | 3,750,277 | 1.08 | 12.00 | 479,828 | 44,987,198 | |
2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,076 | 741,627 | 0.55 | 14.99 | 61,096 | 11,116,395 | |
2012-11-19 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12,515 | 737,551 | 1.73 | 15.26 | 190,926 | 11,251,931 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 17,400 | 1,052,258 | 1.68 | 4.01 | 69,718 | 4,216,187 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 31,929 | 1,827,856 | 1.78 | 4.01 | 127,933 | 7,323,853 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 8,800 | 1,034,858 | 0.86 | 4.08 | 35,915 | 4,223,462 | |
2012-11-09 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 14,300 | 1,795,927 | 0.80 | 4.08 | 58,361 | 7,329,537 | |
2012-11-08 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
P - Purchase | 40,000 | 3,750,277 | 1.08 | 12.00 | 479,828 | 44,987,198 | |
2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 4,076 | 741,627 | 0.55 | 14.99 | 61,096 | 11,116,395 | |
2012-11-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 12,515 | 737,551 | 1.73 | 15.26 | 190,926 | 11,251,931 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 21,500 | 1,026,058 | 2.14 | 4.05 | 87,150 | 4,159,126 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 36,100 | 1,781,627 | 2.07 | 4.05 | 146,331 | 7,221,825 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
CommonStock |
P - Purchase | 23,400 | 1,004,558 | 2.38 | 4.05 | 94,688 | 4,064,944 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 6,700 | 1,745,527 | 0.39 | 4.05 | 27,112 | 7,063,275 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 5,300 | 981,158 | 0.54 | 4.06 | 21,495 | 3,979,283 | |
2012-11-02 |
|
4 | TRGT |
TARGACEPT INC
Common Stock |
P - Purchase | 46,700 | 1,738,827 | 2.76 | 4.06 | 189,401 | 7,052,161 | |
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
1,692,127 | ||||||||
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
975,858 | ||||||||
2012-09-10 | 3 | TRGT |
TARGACEPT INC
Common Stock, $0.001 par value |
349,482 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
651,640 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
376,150 | ||||||||
2012-08-31 | 3 | CCXI |
ChemoCentryx, Inc.
Common Stock, $0.001 par value |
3,710,277 |